Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising over RMB 100 million (USD 14.46 million). The round was led by LongRiver Jiangyuan Investment, with additional participation from Nanshan Zhanxin Investment, Junshi Venture Capital, Boyuan Capital, and Qingsong Capital. Existing investor Genesis Venture also continued its investment, demonstrating continued confidence in the company’s growth trajectory. The funds raised will be used to accelerate the clinical progress of Oculgen’s multi-antibody pipeline in both China and the United States, providing a solid financial foundation for the company’s further development.
Company Focus and Achievements
Oculgen is dedicated to the research and development of innovative large-molecule drugs for common ophthalmic diseases. The founding team, leveraging their extensive experience in ophthalmic drug development, has made significant progress, achieving remarkable results in 2024. The company’s core product, OCUL101, which holds exclusive intellectual property rights, has been particularly outstanding. Since its establishment, Oculgen has completed dual filings in China and the United States within just two years. OCUL101 received clinical trial approvals from the FDA and CDE on November 19, 2024, and January 9, 2025, respectively, becoming the world’s first dual-target, triple-effect innovative antibody (uniquely targeting neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA)).
OCUL101: A Global First
OCUL101 is poised to become the first domestic drug targeting GA and the world’s first ophthalmic drug covering all three aforementioned indications. This breakthrough offers new treatment hope for millions of patients in China who currently have no viable treatment options and provides a new therapeutic alternative for common ophthalmic diseases globally. The funds from this round will be used to efficiently advance the clinical trials of OCUL101 in both China and the United States. Oculgen is committed to accelerating drug development, bringing this hope to reality as soon as possible.-Fineline Info & Tech
